Bridgeway Capital Management Inc. increased its position in shares of Protagonist Therapeutics Inc (NASDAQ:PTGX) by 69.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 85,600 shares of the company’s stock after purchasing an additional 35,000 shares during the quarter. Bridgeway Capital Management Inc. owned 0.35% of Protagonist Therapeutics worth $881,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Eqis Capital Management Inc. acquired a new position in Protagonist Therapeutics in the second quarter valued at approximately $236,000. LMR Partners LLP acquired a new position in Protagonist Therapeutics in the second quarter valued at approximately $210,000. Bank of New York Mellon Corp lifted its holdings in Protagonist Therapeutics by 26.6% in the second quarter. Bank of New York Mellon Corp now owns 63,269 shares of the company’s stock valued at $426,000 after acquiring an additional 13,303 shares during the period. American Century Companies Inc. lifted its holdings in Protagonist Therapeutics by 3.7% in the second quarter. American Century Companies Inc. now owns 148,076 shares of the company’s stock valued at $995,000 after acquiring an additional 5,242 shares during the period. Finally, Spark Investment Management LLC lifted its holdings in Protagonist Therapeutics by 69.3% in the second quarter. Spark Investment Management LLC now owns 138,300 shares of the company’s stock valued at $929,000 after acquiring an additional 56,600 shares during the period. 66.20% of the stock is owned by hedge funds and other institutional investors.
PTGX has been the subject of a number of analyst reports. Zacks Investment Research downgraded Protagonist Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 10th. Nomura initiated coverage on Protagonist Therapeutics in a report on Thursday. They issued a “buy” rating and a $13.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the stock. Protagonist Therapeutics has an average rating of “Hold” and a consensus target price of $20.50.
Shares of NASDAQ:PTGX opened at $6.73 on Friday. Protagonist Therapeutics Inc has a 12-month low of $5.49 and a 12-month high of $23.97. The company has a market capitalization of $154.07 million, a price-to-earnings ratio of -3.22 and a beta of 3.30.
Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Tuesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.01). Protagonist Therapeutics had a negative net margin of 70.54% and a negative return on equity of 24.08%. The company had revenue of $6.12 million during the quarter, compared to analyst estimates of $6.35 million. Equities research analysts predict that Protagonist Therapeutics Inc will post -1.58 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Bridgeway Capital Management Inc. Grows Position in Protagonist Therapeutics Inc (PTGX)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/12/08/bridgeway-capital-management-inc-grows-position-in-protagonist-therapeutics-inc-ptgx.html.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.
Featured Article: Coverage Ratio
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.